New technology to measure molecular interactions in cancer research.
Quantification of molecular interactions across the matrix spectrum enables cancer research.
This study is testing a new technology that helps scientists better understand how molecules interact in cancer, which could lead to earlier detection and better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10918535 on NIH RePORTER |
What this research studies
This research focuses on developing a novel technology called free-solution assay (FSA) combined with a compensated Interferometric reader (CIR) to study molecular interactions in cancer. The approach is unique as it allows for ultra-sensitive, label-free measurements in various biological matrices without the need for enzyme-based methods. By refining this technology, researchers aim to enhance the understanding of cancer biology, improve early detection, and facilitate the discovery of biomarkers. Patients may benefit from advancements in clinical diagnosis and treatment strategies derived from this innovative methodology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from enhanced diagnostic techniques.
Not a fit: Patients with non-cancerous conditions or those not seeking cancer-related diagnostic advancements may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer detection and more effective treatment options for patients.
How similar studies have performed: Other research has shown promise with similar label-free technologies in cancer diagnostics, indicating potential for success in this novel approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Bornhop, Darryl J. — Vanderbilt University
- Study coordinator: Bornhop, Darryl J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.